Abstract
Pioglitazon is an important antidiabeticum from the group of so-called insulin sensitizors ? stimulators of metabolic core receptors PPAR-g. When administered in 15mg (or 30 mg) once a day, a reduction of glycohemaglobin by 1 ? 1.5 % is achieved.
The effect appears gradually in the course of one month and gets higher even after several months of treatment. Pioglitazon is indicated for treatment of type 2 diabetes